期刊
PHARMACOGENOMICS
卷 8, 期 8, 页码 917-931出版社
FUTURE MEDICINE LTD
DOI: 10.2217/14622416.8.8.917
关键词
pharmacoagenecics; pharmacogenomics; pioglitazone; rosightazone; thiazolidinedione; troglitazone
资金
- NIDDK NIH HHS [K23 DK073197] Funding Source: Medline
The thiazoliclinediones (TZDs) are peroxisome proliferator-activated receptor-gamma, agonists and have glucose-lowering, insulin-sensitizing and anti-inflammatory effects. TZDs are approved for the treatment of Type 2 diabetes, and have been studied as a diabetes-prevention strategy. Despite widespread use of TZDs, a large number of patients fail to achieve a substantial reduction in glucose, or an improvement in insulin sensitivity, following treatment. Available data suggest that polymorphisms in genes encoding TZD drug targets, effector proteins and metabolizing enzymes contribute to the observed interindividual variability in TZD response and disposition. The purpose of this review is to highlight recent developments in the field of TZD pharmacogenetics, specifically focusing on clinical studies that have investigated genetic determinants of TZD response (i.e., reduction in glycemia and improvement in insulin sensitivity), disposition (i.e., pharmacokinetics), and side effects in patients with Type 2 diabetes and patients at risk for Type 2 diabetes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据